Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Expansion Is Opening New Pathways For Strategic Investment
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for asthma and chronic obstructive pulmonary disease (COPD) medications has experienced robust expansion over recent years. Projected to rise from $35.66 billion in 2025 to $39.07 billion in 2026, this growth represents a compound annual growth rate (CAGR) of 9.6%. Historical progress has been driven by factors such as increasing rates of smoking, urban air pollution, respiratory care provided in hospital settings, the widespread adoption of inhaler technology, and a rise in asthma diagnoses.
The respiratory drug market, covering asthma and chronic obstructive pulmonary disease (COPD), is projected to experience robust expansion in the coming years. It is anticipated to reach a value of $55.67 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.3%. Key factors driving this forecasted growth include innovation in biologic drugs, an aging population, worsening air quality, the emergence of personalized respiratory therapies, and a shift toward home-based care solutions. Notable trends shaping this period comprise the rising use of combination inhaler therapies, a greater emphasis on long-acting bronchodilators, the expanding role of biologics in managing severe asthma, a move toward managing respiratory conditions at home, and an escalating demand for affordable generic inhalation medications.
Download A Free Sample Report For Comprehensive Market Insights:
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Demand Drivers: What Is Fueling Industry Growth?
The rising frequency of smoking is anticipated to advance the expansion of the asthma and COPD drugs market in the foreseeable future. Smoking is defined as the practice of consuming tobacco products through inhaling smoke, a habit that causes severe health problems like lung cancer and heart disease. This growing trend in smoking is largely fueled by social influences, including peer pressure, cultural standards, and social settings that drive individuals to begin and persist in smoking. Medications for asthma and chronic obstructive pulmonary disease (COPD) counteract the respiratory damage from smoking by decreasing inflammation, relaxing airway muscles, and enhancing airflow, which eases symptoms and boosts lung performance. In 2024, the European Respiratory Society (ERS), a Switzerland-based nonprofit, released a study on youth smoking trends, revealing a significant rise from 22.5% of participants in 2022 to 40.1% in 2024. Consequently, the increasing prevalence of smoking is fueling the growth of the asthma and COPD drugs market.
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Segment Landscape: Which Areas Lead Market Development?
The asthma and chronic obstructive pulmonary disease (copd) drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers
2) By Route Of Administration: Inhalation, Oral, Injection, Other Route Of Administrations
3) By Patient Group: Adult, Pediatric, Geriatric
4) By Application: Asthma, Chronic Obstructive Pulmonary Disease
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores
Subsegments:
1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines
2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids
3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid
4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Innovation Trends: Which Developments Are Transforming The Industry?
Major players in the asthma and chronic obstructive pulmonary disease (COPD) drug market are increasingly turning to innovative combination therapies, including short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS) rescue inhalers, to deliver benefits such as preventing severe asthma episodes, better managing inflammation, and supporting more effective disease control. A SABA–ICS rescue inhaler merges a short-acting beta-agonist, which quickly eases airway muscle tension to alleviate symptoms, with an inhaled corticosteroid, which combats persistent airway inflammation, thus providing dual advantages—swift symptom relief coupled with an anti-inflammatory effect. For example, in January 2024, AstraZeneca, a biopharmaceutical firm headquartered in the UK, introduced AIRSUPRA (albuterol/budesonide) in the United States. This fixed-dose SABA-ICS rescue inhaler is aimed at treating asthma symptoms and averting sudden serious breathing issues, with its two-component formulation delivered through pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA not only enhances quick symptom relief but also targets airway inflammation concurrently, lowering the chance of severe asthma flare-ups and improving overall asthma management.
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Industry Leaders And Market Competition
Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.
Access The Complete Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report:
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
